References
- EMS Bridging Trial Investigators. Combined intravenous/intra-arterial thrombolytic therapy: safety, time-to-treatment, and frequency of clot. (Abstr) Stroke 1996; 27(1): 165
- del Zoppo GJ, Higashida RT, Furlan AJ, et al. The prolyse in acute cerebral thromboembolism trial (PROACT): results of 6 mg dose tier. Stroke 1998; 29(1): 4–11
- Multicentre Acute Stroke Trial—Europe Study Group. Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med 1996; 335(3): 145–50
- Multicentre Acute Stroke Trial-Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet 1995; 346(8989): 1509–14
- Australian Streptokinase (ASK) Trial Study Group. Streptokinase for acute ischemic stroke with relationship to time of administration. JAMA 1996; 276(12): 961–6
- Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274(13): 1017–25
- National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333(24): 1581–7
- Levy DE, Brott TG, Haley EC Jr, et al. Factors related to intracranial hematoma formation in patients receiving tissue-type plasminogen activator for acute ischemic stroke. Stroke 1994; 25(2): 291–7
- Adams HP Jr, Brott TG, Furlan AJ, et al. Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association. Stroke 1996; 27(9): 1711–8
- Practice advisory: thrombolytic therapy for acute ischemic stroke: summary statement. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1996; 47(3): 835–9